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Abstract 
Summary 
Economic evaluations are increasingly used to assess the value of health interventions, but variable quality and 
heterogeneity limit the use of these evaluations by decision-makers. These recommendations provide guidance 
for the design, conduct, and reporting of economic evaluations in osteoporosis to improve their transparency, 
comparability, and methodologic standards. 
Introduction 
This paper aims to provide recommendations for the conduct of economic evaluations in osteoporosis in order 
to improve their transparency, comparability, and methodologic standards. 
Methods 
A working group was convened by the European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis to make recommendations for the design, conduct, and reporting of economic evaluations in 
osteoporosis, to define an osteoporosis-specific reference case to serve a minimum standard for all economic 
analyses in osteoporosis, to discuss methodologic challenges and initiate a call for research. A literature review, 
a face-to-face meeting in New York City (including 11 experts), and a review/approval by a larger group of 
experts worldwide (including 23 experts in total) were conducted. 
Results 
Recommendations on the type of economic evaluation, methods for economic evaluation, modeling aspects, 
base-case analysis and population, excess mortality, fracture costs and disutility, treatment characteristics, and 
model validation were provided. Recommendations for reporting economic evaluations in osteoporosis were 
also made and an osteoporosis-specific checklist was designed that includes items to report when performing an 
economic evaluation in osteoporosis. Further, 12 minimum criteria for economic evaluations in osteoporosis 
were identified and 12 methodologic challenges and need for further research were discussed. 
Conclusion 
While the working group acknowledges challenges and the need for further research, these recommendations 
are intended to supplement general and national guidelines for economic evaluations, improve transparency, 
quality, and comparability of economic evaluations in osteoporosis, and maintain methodologic standards to 
increase their use by decision-makers. 
Keywords 
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A paper endorsed by the Scientific Advisory Board of ESCEO, the Committee of Scientific 
Advisors and the Committee of National Societies of IOF, the US National Osteoporosis 
Foundation and Osteoporosis Canada 
Introduction 
Considering the limited healthcare resources available around the world, as well as recent major innovations in 
the management of osteoporosis, it has become increasingly important for decision-makers to allocate 
healthcare resources efficiently [1]. Economic evaluations that compare interventions in terms of costs and 
outcomes are increasingly used by decision-makers to assess the value of healthcare interventions. In particular, 
economic evaluations now play an important role in pricing and reimbursement decisions [2]. 
In the field of osteoporosis, the number of economic evaluations has increased markedly in recent years [3, 4]. 
Economic evaluations have been conducted to assess the cost-effectiveness of anti-osteoporotic drugs [3, 5, 6], 
to identify cost-effective intervention thresholds for fracture risk [7, 8, 9], and to estimate the cost-effectiveness 
of osteoporosis programs for screening patients [10, 11] or fracture liaison services for secondary fracture 
prevention [12]. Previous economic analyses have suggested that anti-osteoporotic drugs are generally cost-
effective for the treatment of postmenopausal women over the age 60–65 years with low bone mass or an 
additional risk factor such as the presence of a previous fracture and they are generally cost-saving over the age 
of 80 years [3]. It is difficult, however, to make clear comparisons of cost-effectiveness of interventions due to 
differences of study designs, heterogeneity in model structure, assumptions, fracture risk, comparators, and the 
individual country setting [3]. In addition, the variable quality and reporting of these economic evaluations limit 
their comparability and use by decision-makers [3]. 
A number of general and national guidelines and recommendations for the design, conduct, and reporting of 
cost-effectiveness analyses have been produced, including the series of Modelling Good Research 
Practices published by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [13], 
the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist for good reporting of 
economic evaluation [14], and the recommendations for Conduct, Methodological Practices, and Reporting of 
Cost-effectiveness Analyses from the Second Panel on Cost-Effectiveness in Health and Medicine [15]. An 
important limitation of such methodological standards is that they are, of necessity, fairly general and tend to 
neglect the unique circumstances that surround particular clinical context [16]. A few disease-specific guidelines 
have thus been developed to provide additional disease-specific recommendations for economic evaluations 
[16, 17, 18, 19, 20], including one that is outdated in the field of osteoporosis [19]. To supplement the generally 
accepted methodologic standards, disease-specific recommendations for the conduct and reporting of economic 
evaluations can be very useful for improving the quality and use of economic evaluations. 
In recent years, the management of osteoporosis and supportive data has evolved [1]. Incorporating emerging 
evidence about osteoporosis and osteoporosis treatment in a new economic guideline is therefore important. 
Recent evidence includes the development of new osteoporosis treatments (e.g., abaloparatide [21] and 
romosozumab [22]), the value of sequential therapy [23, 24], effect after treatment discontinuation [25], new 
data about imminent risk after fractures [26], and the worldwide increase in the use of fracture risk algorithm 
such as FRAX® [27]. 
The aim of this paper is to provide recommendations for the conduct of economic evaluations in osteoporosis. 
These recommendations, which supplement general and national guidelines, can guide researchers in designing 
appropriate and high-quality economic evaluations and help decision-makers and reviewers to assess the quality 
of these studies. Our study further aims to improve transparency and comparability and maintain methodologic 
standards of these studies. 
More specifically, this study has four objectives: (1) to make recommendations for the design and conduct of 
economic evaluations in osteoporosis; (2) to make recommendations regarding the reporting of economic 
evaluations in osteoporosis, as a complement to the CHEERS checklist [14]; (3) to define an osteoporosis-specific 
reference case to serve a minimum standard for all economic analyses in osteoporosis to reduce inter-study 
heterogeneity facilitating inter-study comparisons; and (4) to discuss methodologic challenges and directions for 
research for economic evaluation in osteoporosis to improve the quality of future studies. 
Methods 
An international working group was formed to develop recommendations for the conduct of economic 
evaluations in the field of osteoporosis. The working group consisted of clinical scientists and health economic 
experts in the field of osteoporosis who were selected by the Scientific Advisory Board of European Society on 
Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). A three-
step process was followed. 
First, in preparation for a working group meeting, MH and SS conducted a literature review to identify a list of 
relevant articles to share with the working group. The literature search was conducted in January 2018 using the 
key terms “economic evaluation or cost-effectiveness” and “osteoporosis” in PubMed. The list of relevant 
articles (n = 17) included a background study on health technology assessment and economic evaluation [1]; 
reviews of economic evaluation in osteoporosis [3, 28]; some examples of published economic evaluations in 
osteoporosis [5, 8, 29, 30, 31]; the technical appendix of a publication [32]; a report of the Institute for Clinical 
and Economic Review in the USA [33]; a report of the National Institute for Clinical Excellence and Health in the 
UK [34]; the CHEERS checklist for good reporting of economic evaluation [14]; the recommendations for 
Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses from the Second Panel on 
Cost-Effectiveness in Health and Medicine [15]; and some disease-specific guidelines for economic evaluations 
[16, 17, 18, 19]. A preliminary list of areas where recommendations would be needed was developed by MH and 
reviewed/completed by SS and JYR. 
Second, a 1-day in-person meeting was conducted on February 12, 2018, in New York City (NYC) to define and 
discuss the recommendations. Specialists in rheumatology, endocrinology, physical medicine and rehabilitation, 
geriatrics, physiotherapy, epidemiology, and health economics, as well as patient representatives (n = 11) were 
invited to participate. The meeting started with four short presentations about emerging evidence about 
osteoporosis treatment options (by KGS), modeling the cost-effectiveness of an osteoporotic treatment (by MH), 
overview and challenges of cost-effectiveness of osteoporosis medications (by SS), and existing guidelines for 
the conduct of economic evaluations (by ANAT). A group discussion led by MH and SS was then conducted to 
define recommendations for the conduct of economic evaluations and to answer all the study’s objectives. Each 
participant had the opportunity to comment on the areas for recommendations and to add additional ones. 
Following the meeting, members of the writing group (MH, JYR, SS, ANAT, and SVB) drafted the 
recommendations for the conduct of economic evaluations and a first report on the meeting consensus; this 
was reviewed and commented on by all participants from the NYC meeting. 
As a third step, the recommendations for the conduct of economic evaluations was sent to a larger group of 
clinical and economic experts from around the world (n = 23) to review, comment on, and validate the 
recommendations. 
The present recommendations were developed independently by the authors, with funding sources having no 
role in the writing or editing of this document. In addition, each member of the working group agreed to declare 
their potential conflict of interest, if any, in the process of article submission. 
Results 
First, it is strongly recommended that the methodological choice, data, and assumptions used in an economic 
evaluation be clearly explained, justified, and referenced. It is further recommended that data inputs and main 
assumptions should be summarized in tables in the main article or in appendices. It is important that authors of 
an economic evaluation provide enough information in a manuscript to allow another researcher to fully 
understand it and potentially replicate it. It is also recommended to use national/local input data as much as 
possible and to be in line with the country-specific osteoporotic fracture clinical management algorithm. 
Recommendations for the design and conduct of economic evaluations in osteoporosis 
The recommendations for the design and conduct of an economic evaluation in osteoporosis are outlined in 
Table 1 and further details are discussed below. 
Table 1 Recommendations for the design and conduct of an economic evaluation in osteoporosis 
Type of economic evaluation 
 • Cost-utility analysis using QALY as outcome 
Method for the conduct of economic evaluation 
 • A model-based economic evaluation 
Modeling technique 
 • Lifetime horizon 
 • Markov model is appropriate (6 months/1 year cycle length) 
 • Avoid hierarchy of fractures and restrictions after fracture events 
 • Hip, clinical vertebral, and non-vertebral non-hip fracture 
Base-case analysis and population 
 • Multiple scenarios: age range, BMD, and fracture risk scenarios 
 • At least a scenario including a 10-year risk of a major osteoporotic fracture equal to 20% or with a BMD T-
score ≤ − 2.5 with or without fractures 
 • The FRAX® or GARVAN® tools can be used to model fracture risk 
 • Increased risk after fracture events within the model 
Mortality 
 • Excess mortality after hip fractures 
 • Proportion attribute to the fracture (e.g., 25–30%) 
Fracture costs and utility 
 • Societal and/or healthcare payer perspective 
 • Acute fracture costs 
 • Long-term costs after hip fracture (attributable to the fracture) 
 • First year and subsequent years’ effects of fractures on disutility 
 • National ICUROS data if available 
 • An additional effect (on costs and/or utility) after multiple fractures 
Treatment characteristics 
 • Treatment duration similar to guidelines or RCTs 
 • Comparators: no treatment and relevant active osteoporotic agent(s) 
 • Sequential therapy may be considered as intervention/comparators 
 • Efficacy data from RCTs, (network) meta-analysis 
 • In the absence of hip/wrist specific efficacy data, use of non-vertebral or clinical fracture efficacy data 
 • Treatment effects after discontinuation depending on treatment 
 • Medication adherence as sensitivity analysis 
 • Drug costs and administration/monitoring costs 
 • Adverse events 
 
Type of economic evaluation 
An economic evaluation compares at least two health interventions in terms of costs and effectiveness 
outcomes. The most frequently used methods are cost-utility analysis (using quality-adjusted life years (QALY) as 
the outcome) and cost-effectiveness analysis that expresses outcomes in natural units such as life years or 
fracture events [1]. The QALY estimator is an attractive outcome measure in the field of osteoporosis because it 
offers the advantage of simultaneously capturing the morbidity and mortality effects of fracture events and thus 
of anti-osteoporosis treatment [28]. The use of the QALY was further endorsed by the 2011 OMERACT 
economics working group for economic studies in musculoskeletal diseases [35] and is the common metric used 
by several national health technology assessment agencies. There are however some limitations of QALY namely 
ethical considerations, methodological considerations and theoretical assumptions, and condition specific 
considerations [36]. Despite these limitations and given the lack of robust alternatives, the QALY is still regarded 
as the most rigorous methodological tool available and it is recommended that QALY be used as the 
effectiveness outcome when conducting an economic evaluation in osteoporosis. Presenting disaggregated 
outcomes such as life years and fracture events is further recommended (see the “Recommendations regarding 
the reporting of economic evaluations in osteoporosis” section) but does not replace the need for a QALY 
analysis. 
Method for the conduct of economic evaluation 
Economic evaluation can be performed alongside randomized controlled trials (RCTs), called trial-based 
economic evaluation, or separately using decision-analytic modeling [1]. A trial-based economic evaluation 
presents, however, some major weaknesses that reduce its usefulness in informing decision-makers about the 
economic value of anti-osteoporosis interventions. These include a failure to compare all relevant options and a 
truncated time horizon [37], as well as the limited generalizability of persons who participate in clinical trials, 
and finally, this approach does not capture the long-term benefits of preventing fractures or long-term sequelae 
of the intervention(s). 
A model-based economic evaluation that uses mathematical techniques to summarize available information 
about a disease and its implications is recommended, especially as the prevention of an osteoporotic fracture, in 
particular of the hip or vertebra, has long-term consequences on costs and outcomes that may not be captured 
by trial data. Modeling is indeed useful to extrapolate beyond clinical trials, to combine multiple sources of 
evidence (e.g., RCTs, epidemiological, clinical, and economic data) and therefore to answer more relevant policy 
questions [38]. A trial-based economic evaluation could be conducted alongside RCTs but should be 
complemented with a model to address the long-term effects of the osteoporosis treatment. 
Modeling technique 
A model-based economic evaluation with a lifetime horizon is recommended to capture the long-term 
consequences of interventions in terms of costs and outcomes. The choice and development of the model 
should follow the ISPOR/SMDM guidelines on modeling [13]. A Markov modeling technique has commonly been 
used in the field of osteoporosis [3] and is appropriate because osteoporosis is a chronic disease characterized 
by a recurrence of events that can be reflected in Markov health states and fracture risk is continuous (but 
changing) over time. The choice of cycle length (e.g., 6 months or 1 year) should be clearly motivated depending 
on treatment duration/adherence and availability of data. It is recommended to use models that simulate 
fracture events where a relative risk reduction for therapy is applied to baseline age-specific fracture incidence 
rates in the population of interest. 
It is optimal to avoid a hierarchy of fractures and restrictions after fracture events (such as the absence of non-
hip fracture after a previous hip fracture or a limit to the number of fracture events), as real-world patients may 
experience any number and type of fractures. This could be done with the use of a Markov microsimulation 
model [29], discrete-event simulation, or by enlarging the number of health states in a Markov cohort model. To 
adequately accomplish this, more data on the effects of multiple fractures on costs and QALY would be 
interesting. 
It is further recommended that hip, clinical vertebral, and non-vertebral non-hip fractures (that are associated 
with osteoporosis [39]) be included. Non-vertebral non-hip fractures could include wrist fracture and/or other 
osteoporotic fractures. Although some (minor) effects of morphometric vertebral fractures on utilities and an 
increased risk of future fractures are recognized, it is recommended at this stage to include only clinical 
osteoporotic vertebral fractures. 
Base-case analysis/population 
It is recommended to analyze multiple scenarios that include age range (e.g., 50 to 80 years) and fracture risk 
levels (e.g., 10-year risk of a major osteoporotic fracture equal to 10%, 20%, and 30%, or with BMD T-
score = or ≤ − 2.5 with and without previous fractures). Base-case population could be based on reimbursement 
criteria currently in place or on guidelines like those of the American Association of Clinical Endocrinologists 
(AACE) which define high risk in the USA [40]. 
It is acknowledged that defining a single–reference case scenario is difficult since the definition of high-risk 
patients and local reimbursement criteria differs between countries. It is however recommended that at least 
one scenario including a 10-year risk of a major osteoporotic fracture equal to 20% or a population with a BMD 
T-score ≤ − 2.5 at one or two age cohorts (such as 65 and/or 70 years) be conducted. It is recommended to 
conduct more than one of these scenarios and to include a large age spectrum (e.g., 50–80 years). 
To adequately represent the fracture risk of the population of interest, fracture risk from the general population 
needs to be adjusted according to BMD level [41] or the presence of fracture risk factor such as previous 
fractures. FRAX® or the GARVAN® tools that estimate a 5- and/or 10-year probability/incidence of fractures can 
be used to model fracture risk and to assess the effect of different population risks. 
It is further recommended, during design of the model, to incorporate an increased risk after new fracture 
events, in line with studies suggesting an increased fracture risk after fracture [26, 42]. 
Mortality 
Modeling national probabilities of death and to apply a relative risk increase due to fracture events are 
recommended. An excess mortality after hip fractures and clinical vertebral fractures should be modeled, as this 
has been widely demonstrated [43, 44]. An excess mortality after non-hip non-vertebral fractures could be 
modeled once further data will become available. A scenario including only an excess mortality after hip 
fractures should be included (see the “Recommendations regarding the reporting of economic evaluations in 
osteoporosis ” section). Taking into account that only a proportion of excess mortality observed in previous 
studies could be attributable to the fracture event is further recommended. Levels of 25%–30% [44, 45] have 
frequently been associated with hip fracture based on published studies. 
Fracture costs and utilities 
Resource use and cost data should be derived from the national/local setting for the analysis. A societal and/or a 
payer perspective according to local HTA guideline are recommended for the cost assessment. The societal 
perspective includes healthcare, patient and family costs and productivity losses. Acute costs of managing a 
fracture need to be included for all fractures. Hip fractures are also associated with increased admission to long-
term care facilities. This needs to be included for example by incorporating the probability of admissions to 
nursing home following hip fractures. For the long-term cost of nursing homes, it is important to include only 
costs attributable to the fracture. In the absence of sufficient data, it is recommended to not include long-term 
costs for non-hip fractures. 
For utility values, using the age-specific population norms and applying the disutility multipliers following 
fractures by fracture site (first year and subsequent years) are recommended [46]. National ICUROS data are 
recommended if available. Overall ICUROS [47, 48] could be used in the absence of national data for utility. For 
the collection of new utility data, the EQ-5D-5L questionnaire is recommended [49] using a relevant national 
valuation set. Data from ICUROS may allow adjusting baseline, while data from neighboring countries with 
similar characteristics could be considered if national data are not available. An additional effect (on costs 
and/or utility) after multiple fractures could also be modeled although further data would be needed. 
Treatment characteristics 
Modeling an anti-osteoporotic treatment for duration of time similar to RCTs, indications, or guidelines (e.g., 3 
or 5 years for antiresorptive, 12–24 months for anabolics) is recommended. If sequential data are available, 
longer treatment may be considered with an anabolic followed by antiresorptive. 
The list of comparators should include “no treatment” (still the current standard of care in most cases especially 
for primary prevention) and active comparators that are relevant for decision-makers. The purpose of the 
comparison should be clearly stated. With emerging evidence about the value of sequential therapy [24, 50, 51], 
sequential therapy could also be included in intervention/comparators. Comparators to sequential therapy 
could include monotherapy or other anabolic-antiresorptive combinations. 
Efficacy data from treatment should be derived from RCT or meta-analysis, and be fracture site specific. 
Network meta-analysis should also be used for indirect comparisons between drugs. Confidence intervals need 
to be included and used in the model in the probabilistic sensitivity analyses. Some anti-osteoporotic agents do 
not have efficacy data at the hip or wrist. It is recommended to use the reduction in non-vertebral or clinical 
fracture rate with treatment as a surrogate for reduction in hip fracture rate in the base case. This assumption 
should be tested in sensitivity analyses and observational studies or systematic reviews of multiple RCTs (with 
preference for using pooled individual level analysis) would be interesting to confirm it. 
Effects of treatment discontinuation need to be modeled and can be different between drug options and be 
supported by the evidence that is available for the drug options being evaluated. For oral bisphosphonates, a 
linear decrease in treatment effectiveness for a duration similar to treatment duration is commonly assumed [3] 
based on studies assessing bone loss after discontinuation [52] and fracture data [53]. A longer effect for 
anabolic agents should be assumed [54, 55] and a limited effect after discontinuation of denosumab should be 
included in line with recent studies suggesting rapid bone loss and increased risk of multiple vertebral fractures 
[56]. 
It is recommended that all therapy costs be included. Drug costs need to be derived from official drug prices 
listing in the country in which the study is being conducted. In the USA, there is substantial variability in prices 
and the average wholesale price (AWP) could be recommended. In addition to drug cost, administration costs 
need to be included, such as regular visits to general practitioner (e.g., one per 6 months in line with previous 
economic evaluations), BMD measurement (e.g., once per 2 years), and injection/infusion cost. 
The use of real-world medication adherence in an alternative scenario is recommended, as well as sensitivity 
analyses varying adherence levels. Adherence to anti-osteoporosis medications could be poor in real life and 
affect clinical and economic outcomes [57]. Approaches and examples to incorporate medication adherence in 
economic evaluations in osteoporosis have been published [58, 59, 60]. 
Finally, important side effects or extra-skeletal benefits of treatments that have an impact on costs and/or utility 
need to be included. This is especially true for drugs like raloxifene that also reduces the risk of breast cancer. 
Model validation 
The model needs to be validated in line with the ISPOR/SMDM guidelines for model transparency and validation 
including face validity, internal validity, cross validity external validity, and predictive validity [61]. Especially, it is 
important that the model replicates all population estimates for each individual parameter [19]. Validation 
process should be described and reported (e.g., by estimating the number of fractures produced by the model, 
lifetime risk of fracture, or life expectancy and comparing them to (epidemiological) data). 
Recommendations regarding the reporting of economic evaluations in osteoporosis 
It is recommended to use the CHEERS checklist for reporting the economic evaluation (and include it as an 
appendix of the paper). The CHEERS proposes a checklist of 24 items, each with a corresponding 
recommendation. This checklist has achieved widespread recognition and acceptance in health economics [14]. 
For the presentation of results and sensitivity analyses, recommendations are as follows: 
• Present disaggregated outcomes (such as fracture events, life years, therapy/drug costs, other 
healthcare costs) for the intervention and comparator(s) 
• Present incremental costs and outcomes between intervention and comparator(s) 
• Report incremental cost-effectiveness ratio (in terms of costs per QALY gained) 
• Characterize uncertainty and heterogeneity by the conduct of: 
Single-case scenario (defined previously) 
Multiple scenarios (age segment; fracture risk) 
One-way sensitivity analyses presented in tables or tornado diagrams 
Probabilistic sensitivity analyses presented in cost-effectiveness acceptability curves. 
Several one-way sensitivity analyses should be conducted on fracture costs (e.g., long-term cost), excess 
mortality after fractures, effect of fracture on utility, discount rates and on-treatment characteristics such as the 
treatment effect (e.g., if non-vertebral was used for hip), medication adherence, effect of treatment after 
discontinuation, treatment costs, and side effects. 
For probabilistic sensitivity analyses, using distributions for as many parameters with stochastic uncertainty as 
possible is recommended (following guidelines for economic evaluation [62]). It is especially important to model 
the treatment effects with a distribution (e.g., a log-normal distribution). 
In addition to the CHEERS checklist, it is recommended for authors to report on and justify nine osteoporotic-
specific reporting criteria (see Table 2). This includes the reporting and justification of key modeling aspects 
(choice of model, transition probabilities, effect of fracture on costs, mortality, and utility) and key treatment 
characteristics including the effect of treatment per fracture site, the effect of treatment after discontinuation, 
the inclusion and approach used to model medication adherence, therapy costs, and side effects. 
Table 2 Osteoporosis-specific checklist—specific items to include when reporting economic evaluations on 
osteoporosis* 
Item Item 
no. 
Recommendation Reported on page 
no./line no. 
Transition probabilities 1 Report the transition probabilities and how they were 
estimated (including increased fracture risk) 
  
Excess mortality after 
fractures 
2 Describe approaches and data sources used for the excess 
mortality after fractures 
  
Fractures costs 3 Describe approaches and data sources used for fractures costs   
Fractures effects on 
utility 
4 Describe approaches and data sources used for the effects of 
fractures on utility 
  
Treatment effect during 
treatment 
5 Describe fully the methods used for the identification, 
selection, and synthesis of clinical effectiveness data (per 
fracture site) 
  
Treatment effect after 
discontinuation 
6 Describe fully the methods used for the treatment effect after 
discontinuation 
  
Medication adherence 7 Describe approaches and data sources used for modeling 
medication adherence 
  
Treatment costs 8 Describe approaches and data sources used for therapy costs   
Treatment side effects 9 Describe approaches and data sources used for costs and 
utilities effects of adverse events 
  
*In addition to the CHEERS checklist [14] 
Osteoporosis-specific reference case 
A set of criteria with which all economic evaluations in osteoporosis, at minimum, should comply was also 
developed. Minimum requirements will increase the comparability and assessment of studies as well as 
maintain minimum standards. The set of minimum criteria is based on the recommendations and refers to the 
methods which are of importance in the view of the working group. It may be necessary to deviate from this set 
of minimum criteria, but the reasons and nature of deviations should be well substantiated and clearly 
described. The list of minimum criteria is presented in Table 3, which is explained here below. 
Table 3 A set of minimum criteria for an economic evaluation in osteoporosis 
1) Cost-utility analysis with QALY as outcome 
2) Modeling technique (with limited restrictions) 
3) Long-term (lifetime) horizon 
4) Payer and/or societal perspective 
5) At minimum hip and clinical vertebral fracture 
6) Excess mortality after hip and clinical vertebral fractures 
7) Short-term/long-term effects of fracture on utility 
8) Long-term costs of hip fracture 
9) Treatment characteristics*: effect on fractures during treatment and after discontinuation; medication 
adherence; side effects; therapy costs 
10) Multiple scenarios (age, fracture risk, BMD) 
11) Presentation of disaggregated outcomes, incremental costs, and outcomes for each intervention and 
incremental cost-effectiveness ratios 
12) One-way and probabilistic sensitivity analyses 
*Medication adherence and side effects could be included in sensitivity analyses 
Despite the aforementioned limitations of QALY and given the lack of robust alternatives, the QALY is still 
regarded as the most rigorous methodological tool available for economic evaluation (criterion 1) and allows the 
incorporation of the effects of fractures on both mortality and morbidity. To capture the long-term 
consequences of preventing fractures and thus fully capture the costs and outcomes of anti-osteoporotic 
treatment, a modeling technique is deemed appropriate (criterion 2) and should have a long-term (ideally a 
lifetime) time horizon (criterion 3). The model should at minimum include hip and clinical vertebral fractures 
(criterion 5) and be conducted from at least a payer and/or healthcare perspective (criterion 4) and in line with 
national guidelines. A payer perspective could require a shorter than lifetime time horizon. Excess mortality 
after hip and clinical vertebral fractures should be included (criterion 6), as well as short-term and long-term 
effects of fracture on utility (criterion 7) and long-term costs of hip fracture (criterion 8). Treatment 
characteristics should include effect on fractures during treatment and after discontinuation, medication 
adherence, side effects, and treatment costs (criterion 9). It is further recommended to conduct multiple 
scenarios (criterion 10), to present disaggregated outcomes, incremental costs and outcomes for each 
intervention and ICER (criterion 11) and to conduct one-way and probabilistic sensitivity analyses (criterion 12). 
Some methodologic challenges and call for research of economic evaluations in 
osteoporosis 
Several (methodologic) challenges and areas where further research is needed were identified and are 
organized according to probabilities, mortality, costs and utilities, treatments characteristics, and others. 
Modeling fracture risk after a predefined 10-year risk of fractures 
The use of a 10-year probability of fracture (e.g., 10% or 20% risk of major fractures in the next 10 years) has 
increasingly been used in economic evaluations in osteoporosis [63]. There are some data on long-term risk of 
fractures [64, 65], but cannot account for secular trends in fracture risk or mortality during or after the 10-year 
period. It can be conservatively assumed that the age- and sex-specific fracture risk remains stable or assume 
changes to reflect historical differences in the age-specific fracture incidence. 
Increased risk of fractures after fracture and over time 
There is emerging evidence that fracture risk increases after a fracture, and that this increase depends on 
fracture site and decreases over time, while not returning to baseline risk [26]. Not all economic analyses have 
included an increased risk when a new fracture occurred in the model, and they have often constrained the 
increase risk to a specific fracture site. Further data would be needed to know the effects of several fractures 
(from the same and different sites) on fracture risk, and modeling should better reflect this effect. 
Excess mortality after non-hip non-vertebral fractures 
The working group recognizes the excess mortality after hip fractures; however, a consensus was difficult to 
obtain for clinical vertebral fractures. Most experts suggested that there is an excess mortality after clinical 
vertebral (similar to the effects of hip fracture), while others suggested the need for additional data before 
modeling excess mortality after clinical vertebral fractures. Conducting both scenarios is recommended (with 
and without excess mortality after clinical vertebral fracture) and additional data on the effects of clinical 
vertebral fractures on mortality would be needed. More studies on the duration of the excess mortality 
attributable to the fracture event would also be needed. Recently, a study also suggested a mortality effect after 
non-hip non-vertebral fractures [66] and more studies would be interesting to confirm this. Further work would 
also be needed to address the excess mortality after a fracture that can be directly attributable to the fracture 
event. 
Long-term cost/care after hip fractures 
It is recommended to include the long-term cost/care attributable to hip fractures. However, before that can be 
done, a better understanding of the long-term cost/care and the attribution of fracture to admission to nursing 
homes is needed. Further research addressing fracture-attributable length of stay in long-term care is also 
needed along with research investigating long-term costs following clinical vertebral fractures that is expected 
to differ widely between geographic regions/countries. 
Conceptualization of the societal perspective 
The working group acknowledged great variety in the conceptualization and interpretation of the societal 
perspective in economic evaluations of osteoporosis interventions [67]. We further need additional research on 
what social factors lead to indirect costs in the societal realm and to assess informal care in osteoporosis. How 
we measure caregiver burden and community burden will be especially important. Given that societal factors 
differ widely between societies, more data are needed to investigate and then specify the country-specific 
societal costs of fractures. 
Modeling multiple fractures and their severity 
It is optimal incorporating multiple fractures within the model and avoiding hierarchy of fractures and 
restrictions after fracture events. Further studies would be needed to investigate the cost and utility effects of 
multiple fractures as well as to assess the consequences of fracture severity, especially for vertebral fractures. 
Most previous economic analyses did not include fracture number or severity within the model. 
Appropriate comparators 
Identifying the appropriate comparator for an economic analysis in osteoporosis is rarely straightforward. 
Comparators could be based on treatment guidelines or payer reimbursement. Indirect comparisons are 
especially uncertain because of the differences in baseline fracture risk between RCTs. 
Absence of hip fracture data 
Some RCTs are not powered to detect significant differences in hip fractures due to a small number of events. 
This guidance recommends utilizing the reduction in non-vertebral (or clinical) fracture rate with treatment as a 
surrogate for reduction in hip fracture rate in base case. This assumption should be confirmed using 
observational studies or systematic reviews of multiple RCTs (with preference for using individual data with 
propensity scoring). 
Persistence of treatment effects after discontinuation 
There is a need to better understand the anti-fracture effects of anti-osteoporosis treatment after 
discontinuation for most drug treatment. Longer-term fracture outcome studies after treatment 
discontinuation, especially in real-world settings would be needed. The treatment effects after stopping a 
sequential therapy also require investigation. In the meantime, sensitivity analyses need to be conducted on 
offset time. 
Variation in response based on treatment history 
It is needed to better understand the treatment response based on treatment history for both mono and 
sequential therapy. Some studies have suggested that treatment response may be impacted by previous 
treatment [24]. 
Treatment side effects 
Further research needs to be conducted to adequately incorporate medication side effects in economic models. 
More specifically, research is needed on how we might capture cost for atypical fractures or multiple vertebral 
fractures, and the disutility associated with such events. 
Insufficient data in male 
The working group acknowledged current insufficient fracture data for male. Further studies would thus be 
needed to investigate the efficacy of anti-osteoporotic drugs in male. 
Cost-effectiveness in subpopulations 
There is a further need to better understand the cost-effectiveness of anti-osteoporotic agents in 
subpopulations of patients at higher risk such as those with diabetes, rheumatoid arthritis, or glucocorticoid 
users. Efficacy data on all drug classes in these specific populations are also needed. 
Discussion 
This study provides recommendations for the design, conduct, and reporting of economic evaluations of 
osteoporosis interventions in order to improve transparency, comparability, and to maintain methodologic 
standards. This could finally contribute to a more efficient allocation of resources devoted to osteoporosis 
management. 
These recommendations should be seen as supplemental to general and national guidelines for economic 
evaluations. Disease-specific recommendations for economic evaluations are important in order to characterize 
unique circumstances that surround particular clinical contexts. As an illustration, the CHEERS checklist for 
reporting the economic evaluation, which has achieved widespread recognition and acceptance in health 
economics, is recommended [14]. But given that CHEERS is, of necessity, fairly general, a nine-item 
osteoporosis-specific checklist for reporting economic evaluation that may be more effective for osteoporosis 
was designed to complement CHEERS. 
This project further aimed to identify a minimum set of criteria that an economic evaluation in osteoporosis 
should have. Such a set of criteria could help reduce inter-study heterogeneity as well as define minimum 
standards. This list should be considered only as a minimum set of criteria. 
Our recommendations are intended for any researchers interested in conducting an economic evaluation in the 
field of osteoporosis and also to help decision-makers, reviewers, and editors to assess the quality of these 
studies. It is recommended that researchers check the set of minimum criteria and include the osteoporosis-
specific checklist for reporting in addition to CHEERS in appendices of scientific journals. If the osteoporosis 
health economics community follows these recommendations, this would improve the transparency, quality, 
and comparability of economic evaluations of osteoporosis interventions and this may facilitate and increase its 
use by decision-makers. We acknowledge that it may be necessary to deviate from these recommendations in 
some circumstances, but the reasons and nature of deviations must be well substantiated and clearly described 
by the authors. 
There are limitations to these recommendations that deserve mention. First, although a large group of experts 
worldwide was included and combined with a literature review, a face-to-face meeting, a small writing team, an 
additional and an additional experts review, a more formal group process such as a Delphi panel could have led 
to some differences in recommendations. Second, although these recommendations could be applied to any 
type of osteoporosis intervention, the guidance focused mainly on cost-effectiveness analyses of drug treatment 
rather than on nonpharmacological interventions. Third, recommendations were not possible for all aspects of 
model-based economic evaluations in osteoporosis as several methodological challenges of economic 
evaluations requiring further research were identified. In addition, no recommendation on thresholds to define 
an intervention cost-effective was provided, as this question is out of the scope of this study and depends on 
national recommendations. Finally, evaluating the effect of implementation of these recommendations on the 
quality of future economic evaluations in osteoporosis should be considered. Although some disease-specific 
recommendations for economic evaluations have been developed [16, 17, 18, 19], this study is one of the first 
that provides a list of recommendations and minimum requirements for the design, conduct, and reporting of an 
osteoporosis-specific economic evaluation. 
In conclusion, these recommendations are provided as a supplement to general and national guidelines for 
economic evaluations and are intended to improve the transparency, quality, and comparability of economic 
evaluations in osteoporosis. Promoting high-quality methodology standards has the potential to increase their 
use by decision-makers and to lead to a more effective allocation of resources. 
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